SCHEMBL8250775

SCHEMBL8250775

CC1CCC(CCCCS(=O)(=O)O)CC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.35
HRH1 P35367 1/20 0.35
PKM P14618 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
LMNA P02545 1/20 0.33
MAPK1 P28482 1/20 0.33
INPP5A Q14642 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
POLB P06746 1/20 0.31
HPGD P15428 1/20 0.31
KDM5A P29375 1/20 0.30
KDM7A Q6ZMT4 1/20 0.30
KDM4C Q9H3R0 1/20 0.30
PHF8 Q9UPP1 1/20 0.30
KDM2A Q9Y2K7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14491829 0.89 INPP5A (0.34) APPINPP5A
SCHEMBL3105507 0.83 APP (0.44) APPPKMALDH1A1HTTMEN1
SCHEMBL12226351 0.82 SIGMAR1 (0.39) APPALDH1A1MEN1KMT2ALMNA
SCHEMBL355314 0.80 SIGMAR1 (0.47) APPMEN1KMT2ASIGMAR1KDM5A
SCHEMBL8322595 0.80 SIGMAR1 (0.47) APPMEN1KMT2ASIGMAR1KDM5A
SCHEMBL5637908 0.78 SIGMAR1 (0.50) APPMEN1KMT2ASIGMAR1KDM5A
SCHEMBL14491825 0.78 CYP1A2 (0.39) APPPKMHTTMEN1KMT2A
SCHEMBL14491824 0.78 INPP5A (0.42) APPPKMHTTMEN1KMT2A
SCHEMBL17338045 0.77 LMNA (0.42) APPLMNA
SCHEMBL17598208 0.76 APP (0.38) APPALDH1A1LMNAINPP5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2014-11-06 US disclosed
US-8835654-B2 Method and compositions for treating amyloid-related diseases BHI LIMITED PARTNERSHIP (CA) 2014-09-16 US disclosed
US-20140107027-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BHI LIMITED PARTNERSHIP (CA) 2014-04-17 US disclosed
US-20120015911-A1 METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES BELLUS HEALTH INC. (CA) 2012-01-19 US disclosed
US-20110021813-A1 PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF KONG XIANQI 2011-01-27 US disclosed
WO-2006099204-A1 SUBSTITUTED 9-ALKYLADENINES AND THE USE THEREOF ADERIS PHARMACEUTICALS, INC. (US) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021813-A1 PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF MPST, TTR, STS APP 86/4885HRH1 3021/4885PKM 2132/4885
US-20140329746-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 APP 1/4885HRH1 1975/4885PKM 2493/4885
US-20140107027-A1 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 APP 1/4885HRH1 1975/4885PKM 2493/4885
US-20120015911-A1 METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES APP, PSEN1, PSEN2 APP 1/4885HRH1 2036/4885PKM 2249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.